Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress Read more about Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Two Pivotal Vectibix(R) Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology Read more about Two Pivotal Vectibix(R) Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN(R) and PROCRIT(R) (Epoetin alfa) Read more about Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN(R) and PROCRIT(R) (Epoetin alfa)
Amgen and Pfizer Introduce 'Psophisticated Style: A Guide to Everyday Style and Psoriasis(TM)' Hosted by Tim Gunn Read more about Amgen and Pfizer Introduce 'Psophisticated Style: A Guide to Everyday Style and Psoriasis(TM)' Hosted by Tim Gunn
Amgen to Present at the UBS Global Life Sciences Conference Read more about Amgen to Present at the UBS Global Life Sciences Conference
Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference Read more about Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
Amgen to Present at the Baird Healthcare Conference Read more about Amgen to Present at the Baird Healthcare Conference
Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial Read more about Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial
Amgen's Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38 Read more about Amgen's Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38
2010 Addressing Psoriasis(TM) Contest Winners Attend a Style Consultation with Tim Gunn in New York City Read more about 2010 Addressing Psoriasis(TM) Contest Winners Attend a Style Consultation with Tim Gunn in New York City
